Core Insights - The company reported a net income of RMB 178,000 for the six months ending June 30, 2025, with R&D expenses amounting to RMB 26.294 million and a loss per share of RMB 0.25 [1] - Significant progress has been made in technological innovation, product pipeline, and business operations in both the US and China [1] - The company has established a pipeline of six investigational drugs targeting chronic diseases, focusing on the treatment of metabolic diseases and their complications [1] Financial Performance - The company recorded a net income of RMB 178,000 for the reporting period [1] - R&D expenditures totaled RMB 26.294 million [1] - The loss per share was reported at RMB 0.25 [1] Product Development - The company’s core strategy emphasizes continuous innovation in the treatment of metabolic diseases [1] - Multiple candidate drugs are assessed to have dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC) [1] - The NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] Future Outlook - The company anticipates that financial performance will fluctuate due to the development status of candidate drugs, potential collaboration timelines, regulatory approval schedules, and commercialization efforts [1]
派格生物医药-B发布中期业绩，研发开支2629.4万元 已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵